| Product Code: ETC7624821 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Benign Prostatic Hyperplasia Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Benign Prostatic Hyperplasia Market - Industry Life Cycle |
3.4 Ireland Benign Prostatic Hyperplasia Market - Porter's Five Forces |
3.5 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume Share, By Distribution Channels, 2021 & 2031F |
4 Ireland Benign Prostatic Hyperplasia Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of benign prostatic hyperplasia in Ireland |
4.2.2 Growing awareness about available treatment options |
4.2.3 Technological advancements in diagnosis and treatment of benign prostatic hyperplasia |
4.3 Market Restraints |
4.3.1 High cost associated with treatment options |
4.3.2 Limited reimbursement policies for benign prostatic hyperplasia treatments |
4.3.3 Stringent regulatory requirements for approval of new treatments |
5 Ireland Benign Prostatic Hyperplasia Market Trends |
6 Ireland Benign Prostatic Hyperplasia Market, By Types |
6.1 Ireland Benign Prostatic Hyperplasia Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume, By Alpha-Blockers, 2021- 2031F |
6.1.4 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume, By 5- Alpha-Reductase Inhibitors (5-Aris), 2021- 2031F |
6.1.5 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume, By Alpha-Adrenergic Blockers, 2021- 2031F |
6.1.6 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume, By Phosphodiesterase-5 Enzyme Inhibitors, 2021- 2031F |
6.1.7 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume, By Other Drug Types, 2021- 2031F |
6.2 Ireland Benign Prostatic Hyperplasia Market, By Distribution Channels |
6.2.1 Overview and Analysis |
6.2.2 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.2.3 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.2.4 Ireland Benign Prostatic Hyperplasia Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 Ireland Benign Prostatic Hyperplasia Market Import-Export Trade Statistics |
7.1 Ireland Benign Prostatic Hyperplasia Market Export to Major Countries |
7.2 Ireland Benign Prostatic Hyperplasia Market Imports from Major Countries |
8 Ireland Benign Prostatic Hyperplasia Market Key Performance Indicators |
8.1 Average age of diagnosis of benign prostatic hyperplasia in Ireland |
8.2 Number of urologists specializing in benign prostatic hyperplasia treatments |
8.3 Patient satisfaction with current treatment options |
9 Ireland Benign Prostatic Hyperplasia Market - Opportunity Assessment |
9.1 Ireland Benign Prostatic Hyperplasia Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Ireland Benign Prostatic Hyperplasia Market Opportunity Assessment, By Distribution Channels, 2021 & 2031F |
10 Ireland Benign Prostatic Hyperplasia Market - Competitive Landscape |
10.1 Ireland Benign Prostatic Hyperplasia Market Revenue Share, By Companies, 2024 |
10.2 Ireland Benign Prostatic Hyperplasia Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here